Sai Parenterals Limited (SAIPARENT) — FY26 Annual Report | 19 August 2026

Sai Parenterals Limited (NSE: SAIPARENT) announced its 25th AGM scheduled for 10 September 2026 via video conference, with shareholders approving key resolutions including re-appointment of directors, ESOP Scheme 2025 ratification, and a material related-party loan to Noumed Pharmaceuticals Pty Ltd. The filing details financial performance for FY 2025-26, showing revenue of ₹3,809.98 crore, PAT of [amount context mismatch] crore, and EBITDA margin of 12.39%. It outlines strategic expansion through acquisitions like Noumed Pharmaceuticals, rooftop solar adoption, and CSR initiatives reaching 50,000 individuals across 50 villages. The company emphasizes growth in CDMO exports, regulated markets, and international footprint via its Australian subsidiary, with no material uncertainties identified in its audit report.